Abstract:Cyclin-dependent kinases (CDKs) belong to a family of multifunctional enzymes that control cell cycle modifications, transcription, and cell proliferation. Their dysfunctions result in different diseases like cancer making them an important drug target in oncology and beyond. The present study aims at identifying the selective inhibitors for ATP binding site in CDK proteins (CDK1, CDK2, CDK4, and CDK5) following a multi-target drug designing approach. Significant challenges lie in identifying the selective inhibitor for the ATP binding site as this region is highly conserved in all protein kinases. Molecular docking coupled with molecular dynamics simulation and free energy of binding calculations (MMPBSA/MMGBSA) were used to identify the potent competitive ATP binding site inhibitors. All the four proteins were docked against the library of drug-like compounds and the outcomes of the docking study were further analyzed by Molecular dynamics (total of 6μs) and MMPB/GBSA techniques. Five different inhibitors for structurally distant protein kinases, i.e. CDK1, CDK2, CDK4, and CDK5 are identified with the binding energy (ΔGbind-PB) in the range −18.24 to −28.43Kcal/mol. Mechanistic complexities associated with the binding of the inhibitor are unraveled by carefully analyzing the MD trajectories. It is observed that certain residues (Lys33, Asp127, Asp145, Tyr15, Gly16, Asn144) and regions are critical for the retention of inhibitors in active pocket, and significant conformational changes take place in the active site region as well as its neighbor following the entry of the ligand inside active pocket as inferred by RMSD and RMSF. It is observed that LIG3 and LIG4 are the best possible inhibitors as reflected from their high binding energy, interaction pattern, and their retention inside the active pocket. This study will facilitate the process of multi-target drug designing against CDK proteins and can be used in the development of potential therapeutics against different diseases.Graphical Communicated by Ramaswamy H. Sarma

Targeting mTOR Kinase with Natural Compounds: Potent ATP-Competitive Inhibition Through Enhanced Binding Mechanisms

Furthering the Design and the Discovery of Small Molecule ATP-competitive Mtor Inhibitors As an Effective Cancer Treatment

Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment.

Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and Immunotherapy

Biochemical and Pharmacological Inhibition of Mtor by Rapamycin and an ATP-Competitive Mtor Inhibitor

Targeting mTOR globally in cancer: thinking beyond rapamycin.

Discovery and Development of ATP-Competitive Mtor Inhibitors Using Computational Approaches.

Biochemical, Cellular, and in Vivo Activity of Novel Atp-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin

ATP-competitive Inhibitors of the Mammalian Target of Rapamycin: Design and Synthesis of Highly Potent and Selective Pyrazolopyrimidines.

Potent, Selective, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin Kinase Domain Exhibiting Single Agent Antiproliferative Activity.

Binding site hotspot map of PI3Kα and mTOR in the presence of selective and dual ATP-competitive inhibitors

mTOR Signaling, Function, Novel Inhibitors, and Therapeutic Targets

Targeting Mtor for Cancer Therapy

Mtor-Targeted Therapy: Differential Perturbation to Mitochondrial Membrane Potential and Permeability Transition Pore Plays a Role in Therapeutic Response.

Mechanisms of Rapamycin Inhibition on Mtor and Drug Design

Exploring multi-target inhibitors using in silico approach targeting cell cycle dysregulator–CDK proteins

Turning down PI3K/AKT/mTOR signalling pathway by natural products: an in silico multi-target approach

Targeting Mtor for Fighting Diseases: A Revisited Review of Mtor Inhibitors

Overview of Research into mTOR Inhibitors

Insights into the Role of mTOR/AMPK as a Potential Target for Anticancer Therapy

The allosteric mechanism of mTOR activation can inform bitopic inhibitor optimization